Teva Pharmaceutical Industries (TEVA) DIvidends Date & History

Key Takeaways

• Teva Pharmaceutical Industries (TEVA) currently pays no dividend, with a forward dividend yield of 0%.
• The company suspended its quarterly dividend in late 2017 as part of a broader deleveraging and restructuring effort.
• Teva's accumulated deficit legally restricts its ability to pay dividends or repurchase shares.
• Debt reduction has progressed, with total debt falling from $19.8 billion in 2023 to $17.8 billion at the end of 2024.
• With no payout, Teva offers no current income and is generally unsuitable for income-focused dividend investors today.

Dividend Overview

Teva Pharmaceutical Industries Ltd., the Israel-based generic and specialty pharmaceutical company, does not currently pay a dividend to shareholders. Its dividend yield stands at 0%, and no upcoming ex-dividend or payment dates are scheduled. This means TEVA is neither a high-yield stock nor a dividend growth stock at present.

Historically, Teva distributed quarterly dividends for decades, but management suspended the payout in late 2017 amid heavy debt taken on to fund its acquisition of Actavis Generics. Since then, capital allocation has prioritized debt repayment, litigation costs, and operational turnaround over shareholder distributions. For investors, Teva's dividend profile is defined not by yield or growth, but by the absence of a payout and the conditions that could eventually lead to its reinstatement.

Dividend History and Growth

Teva paid dividends for more than three decades, with records showing regular quarterly distributions dating back to 1985. For years, the company raised its dividend steadily, reflecting its once-dominant position in the global generics market. However, that streak ended abruptly in December 2017, when management announced the suspension of the dividend to preserve cash and reduce leverage following a period of intense competitive pressure on its generic drug portfolio and significant legal settlements.

Since the suspension, TEVA has not reinstated a dividend. The company's dividend growth rate over the past five years is effectively 0%, and there is no current dividend growth streak. The suspension highlights how quickly a long dividend record can end when a company's balance sheet comes under stress, and it serves as a reminder that past distributions are not a guarantee of future payments.

Dividend Sustainability and Payout Ratio

Because Teva pays no dividend, its payout ratio is 0%, and there are no earnings or free cash flow (FCF) to allocate toward distributions. The more relevant question is whether the company is financially positioned to reinstate a dividend in the future.

Teva's financial position has improved but remains constrained. The company reported revenues of $16.5 billion in 2024, up 4% year over year, but posted an operating loss of $303 million for the year. More significantly, the company continues to carry an accumulated deficit, which under applicable law restricts its ability to pay dividends or repurchase shares. As management has stated in regulatory filings, Teva "currently cannot conduct share repurchases or pay dividends due to our accumulated deficit."

Total debt fell to $17.8 billion at the end of 2024, down from $19.8 billion a year earlier, and cash flow from operating activities was approximately $1.25 billion. While deleveraging is progressing, the combination of an accumulated deficit and elevated leverage means a return to dividend payments is not imminent.

Dividend Compared to Industry Peers

Teva's 0% dividend yield places it well below its large pharmaceutical peers. The average dividend yield across the pharmaceuticals industry is roughly 1.9% to 2.0%. By comparison, large-cap peers such as JNJ, PFE, MRK, and BMY all maintain regular quarterly dividends, with several offering yields above 3%.

In this context, TEVA is a clear outlier: a major pharmaceutical company that returns no cash to shareholders through dividends. Investors seeking income within the healthcare sector would need to look to Teva's dividend-paying peers rather than to Teva itself, at least until the company resolves its balance-sheet constraints and elects to restore a payout.

AI Screener

For investors who want to identify dividend stocks, income-focused investments, or trending opportunities across the market, Tickeron's AI Screener offers a powerful, AI-driven discovery tool. The AI Screener lets traders and investors filter thousands of stocks and ETFs using customizable criteria such as industry, market capitalization, technical indicators, price patterns, volatility, and performance metrics. It can help surface dividend-paying stocks, breakout candidates, and other market opportunities far more efficiently than manual screening. Because TEVA pays no dividend, investors focused on income can use the AI Screener to quickly scan for higher-yielding alternatives in the pharmaceuticals sector and beyond.

Is This Stock Attractive for Dividend Investors?

For income-oriented and conservative dividend investors, TEVA is not currently an attractive option, because it offers no yield, no dividend growth, and no near-term path to reinstating a payout given its accumulated deficit. Investors who rely on regular distributions to generate income would find Teva's profile incompatible with their objectives.

That said, the stock may hold appeal for a different type of investor: those focused on capital appreciation and a long-term turnaround story, rather than income. Teva's debt reduction, stabilizing revenues, and efforts to rebuild profitability could eventually create the financial flexibility needed to resume shareholder returns. However, any dividend reinstatement would depend on sustained earnings, continued deleveraging, and the elimination of the accumulated deficit, none of which is guaranteed. Dividend growth investors should therefore monitor Teva's balance-sheet progress, but they would not treat it as a dividend stock today.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations